Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
111In-PSMA-INER-56
- Development stage
- Preclinical
- Lead developer
- National Atomic Research Institute
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
111In-PSMA-INER-56 (also known as 111In-NARI-PSMA or 111In-MH-PC-AB-56) is a long-acting, radiolabeled peptide-based diagnostic imaging agent developed by the National Atomic Research Institute (NARI, formerly the Institute of Nuclear Energy Research or INER) in Taiwan. It is designed to target prostate-specific membrane antigen (PSMA), which is highly overexpressed in prostate cancer and its bone metastases. The molecule features a novel albumin-binding motif (a p-methyl-phenyl group) that extends its blood circulation half-life by binding to serum albumin, allowing for a slow-release mechanism that enhances tumor accumulation and retention. Radiolabeled with indium-111 (111In), it is utilized for single-photon emission computed tomography (SPECT/CT) imaging to visualize PSMA-positive prostate cancer lesions. It forms a theranostic pair with its therapeutic counterpart, 177Lu-PSMA-INER-56.
- Other names
- [111In]In-PSMA-INER-56indium (111In) PSMA-INER-56indium In 111 PSMA-INER-56
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 111In-PSMA-INER-56.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 111In-PSMA-INER-56.